A phase I pharmacodynamic study of CP-751, 871 as neoadjuvant treatment for early breast cancer
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2015
At a glance
- Drugs Figitumumab (Primary)
- Indications Early breast cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 12 Apr 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 03 Apr 2008 New trial record.